Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer
| Autor: | Haonan Lu, Katherine Nixon, Eric O. Aboagye, Natasha Rinne, Christina Fotopoulou, Paula Cunnea |
|---|---|
| Přispěvatelé: | Myrovlytis Trust Limited, Imperial College Healthcare NHS Trust- BRC Funding, Medical Research Council |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Poor prognosis SOCIETY Early Relapse METABOLISM RECOMMENDATIONS Article 1117 Public Health and Health Services Prognostic markers 03 medical and health sciences 0302 clinical medicine Ovarian cancer Internal medicine Biomarkers Tumor Serous ovarian cancer Humans Medicine 1112 Oncology and Carcinogenesis In patient Oncology & Carcinogenesis Retrospective Studies PLATINUM Ovarian Neoplasms Science & Technology business.industry Proportional hazards model Cytoreduction Surgical Procedures Middle Aged Prognosis Cystadenocarcinoma Serous Survival Rate Biological significance 030220 oncology & carcinogenesis CELLS Cohort Biomarker (medicine) Female business Life Sciences & Biomedicine Follow-Up Studies |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| Popis: | Background: Maximal effort cytoreductive surgery is associated with improved outcomes in advanced high-grade serous ovarian cancer (HGSOC). However, despite complete gross resection (CGR), there is a percentage of patients who will relapse and die early. The aim of this study is to identify potential candidate biomarkers to help personalise surgical radicality. Methods: 136 advanced HGSOC cases who underwent CGR were identified from three public transcriptomic datasets. Candidate prognostic biomarkers were discovered in this cohort by Cox regression analysis, and further validated by targeted RNA-sequencing in HGSOC cases from Imperial College Healthcare NHS Trust (n = 59), and a public dataset. Gene set enrichment analysis was performed to understand the biological significance of the candidate biomarker. Results: We identified ALG5 as a prognostic biomarker for early tumour progression in advanced HGSOC despite CGR (HR = 2.42, 95% CI (1.57–3.75), p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink